Chiasma to Report Third Quarter 2020 Results on November 5
Chiasma (NASDAQ: CHMA) announced a conference call and webcast scheduled for November 5, 2020, at 5:00 PM ET. The event will cover the financial results for the quarter ending September 30, 2020, along with a business update. Investors can participate via domestic and international phone lines or through the company's webcast. An archived version will be available for one year post-event.
Chiasma, headquartered in Needham, MA, focuses on developing oral therapies for patients with chronic diseases.
- None.
- None.
Company to host conference call and webcast at 5:00 p.m. ET
NEEDHAM, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00 pm Eastern Time to discuss financial results for the quarter ended September 30, 2020 and to provide a business update.
Conference Call Details
Thursday, November 5th @ 5:00 pm Eastern Time
| Domestic: | 855-327-6837 |
| International: | 631-891-4304 |
| Conference ID: | 10011435 |
| Webcast: | http://public.viavid.com/index.php?id=141919 |
A live audio webcast of the call may also be accessed under "Events & Presentations" on the News & Investors section of the Company's website, https://ir.chiasma.com/events-presentations. An archived replay of webcast will be available on the Company’s website approximately two hours after the event. The archived webcast will be available for one year.
About Chiasma
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company’s website at www.chiasma.com.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
Media Relations:
Patrick Bursey
LifeSci Communications
646-876-4932
pbursey@lifescicomms.com
FAQ
What is the date and time of Chiasma's conference call?
How can I join the Chiasma conference call?
What will Chiasma discuss during the conference call on November 5, 2020?
Where can I find the webcast for Chiasma's conference call?
How long will the archived Chiasma conference call be available?
